
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1115 | 1021 | 1089 | 1339 | 1769 | 1642 |
Fund Return | 11.54% | 2.08% | 8.9% | 10.21% | 12.08% | 5.09% |
Place in category | 393 | 341 | 505 | 524 | 443 | 471 |
% in Category | 14 | 13 | 22 | 27 | 28 | 47 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
AllianzIncome Growth P H2EUR | 53.17B | 0.29 | 5.16 | 4.99 | ||
AllianzIncome Growth A H2EUR | 53.17B | 0.04 | 4.60 | 4.37 | ||
AllianzIncome Growth IT H2EUR | 53.17B | 0.25 | 5.30 | 5.08 | ||
AllianzIncome Growth CT H2EUR | 53.17B | -0.25 | 3.78 | 3.54 | ||
AllianzIncome Growth RT H2EUR | 53.17B | 0.22 | 5.11 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
European Growth Fund Y DIST EUR | 66.66M | 8.99 | 11.66 | 5.40 | ||
European Growth Fund A DIST Eue | 6.8B | 8.67 | 10.73 | 4.53 | ||
European Growth Fund A Acc EUR | 177.14M | 8.62 | 10.71 | 4.53 | ||
European Growth Fund E Acc EUR | 23.61M | 8.29 | 9.89 | 3.74 | ||
European Growth Fund Y Acc EUR | 186.04M | 9.03 | 11.66 | 5.40 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Allianz Eurp Eq pwrd by Artfcl IntlgcWT€ | LU2397364675 | 8.01 | - | - | |
SAP | DE0007164600 | 2.55 | 253.100 | -0.98% | |
Roche Holding Participation | CH0012032048 | 2.35 | 260.10 | -0.23% | |
AstraZeneca | GB0009895292 | 2.32 | 10,390.0 | -0.12% | |
Novartis | CH0012005267 | 2.31 | 98.43 | +0.54% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Neutral | Buy | Buy |
Technical Indicators | Sell | Strong Buy | Strong Buy |
Summary | Neutral | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review